-+ 0.00%
-+ 0.00%
-+ 0.00%

Tevogen Bio Expanding Its Pipeline To Include Non-Oncology Products, An Approach Aimed At Maximizing ROI From Its ExacTcell Technology

Benzinga·10/11/2024 16:14:01
Listen to the news
  • Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.
  • Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at maximizing ROI from its ExacTcell™ technology.

WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces updates on its growing therapeutic pipeline, designed to meet the high unmet needs of cancer patients. The company is pursuing a prudent commercialization strategy with a focus on its ExacTcell™ technology platform, which leverages precision T cell therapies to address supportive care for cancer patients.